Abstract
Hepatitis C is usually treated with interferon or a combination of interferon and ribavirin, but these agents have numerous side effects, and interferon must be given by injection three time a week. An alternative oral medication would be a welcome advance for treating hepatitis C. Amantadine has been reported to have the potential to produce viral suppression in patients with hepatitis C. To gain further knowledge about the effects of amantadine on hepatitis C, we treated 24 patients for 3–12 months (average = 5.5 months; median = 4.5 months) with 100 mg amantadine twice daily. Twelve patients had stage 3 or 4 fibrosis on biopsy. Eleven patients had a fall in viral titer, but complete viral suppression was not seen in any patient. Three patients had no viral titer obtained after treatment, but their elevated transaminase levels did not change with treatment. Of the 15 patients with a decrease in enzyme levels, only two patients had normalization. Six patients had side effects during the treatment, but in only one was amantadine stopped solely because of side effects. Based on these results and a literature review, we do not believe amantadine is an effective single agent for the treatment of chronic hepatitis C.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Smith JP: Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 42:1681–1687, 1997
Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kierman TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435, 1981
Wiley TE, Mihalov M, O'Riordan, Layden TJ, Lam NP: Amantadine is not effective in clearing HCV from the serum in patients who are not candidates for interferon therapy. Gastroenterology 114:A1365, 1998
Olmeda M, Khalili M, Perillo RP: Amantadine monotherapy in patients with chronic hepatitis C. Gastroenterology 114:A1316, 1998
Pimstone NR, Yu AS, Akhondi MM, Lumbra LA: End-of-treatment virologic response of chronic hepatitis C with either amantadine or rimantadine. Hepatology 26:217A, 1997
Findor JA, Daruich JR, Bruch-Igartua E, Manero EF, Sorda JA, Nakatsuno M, Rey JA: Amantadine HCl alone and in combination with recombinant alpha IFN 2a during a short term therapy in chronic HCV infection. Hepatology 26:217A, 1997
Bacosi M, Ursitti A, De Angelis, Russo F, D'Alessandri L, Bernardeschi D, Martinelli RMA, Ricci GL: Treatment of HCV chronic infection with amantadine and interferon in elderly patients. Hepatology 28:208A, 1998
Fang JC, Hespenheide EE, Driscoll CJ, Caldwell SH: Amantadine-HCl treatment of chronic hepatitis C. Hepatology 26:217A, 1997
Lynch PJ, Peters MG, Lowell JA, Shenoy S, Howard TK, Caldwell CA: Amantadine therapy for recurrent hepatitis after liver transplantation. Hepatology 28:347A, 1998
Senturk H, Mert A, Akdogan M, Tabek F, Turkoglu S, Basaran G, Ozbay G, Badur S: Amantadine monotherapy of chronic hepatitis C patients infected with genotype 1b. Hepatology 28:373A, 1998
El-Zayadi A, Selim O, Shawky S, Moustafa I, El-Taweel A: A controlled study of amantadine monotherapy vs amantadine combined with interferon-α. Hepatology 28:473A, 1998.
Parolin MB, Lacerrda MA, Lopes RW. Amantadine-HCL treatment of chronic hepatitis C in non-responders to alpha-interferon. Hepatology 28:714A, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Goff, J.S., Reveille, R.M. & Johnson, J. Treatment of Chronic Hepatitis C with Amantadine. Dig Dis Sci 45, 1389–1391 (2000). https://doi.org/10.1023/A:1005516322593
Issue Date:
DOI: https://doi.org/10.1023/A:1005516322593